우크라이나 사태를 바라보면서 – 3월 18일까지 전쟁 상황

성광용 문예운동사 2022 수필시대 Vol.20 No.여름

급성 신우신염에서 Gentamicin 1일 1회 요법과 분할 요법의 효과 및 부작용 비교

김양리,성광용,송치원,신우승,조은주,최정현,강문원 대한감염학회 1997 감염 Vol.29 No.2

목적:급성 신우신염 환자를 대사응로 gentamicin 1일 1회 요법과 분할 요법의 효과 및 부작용을 비교하였다. 방법:분할 투여군은 Gentamicin 3-5mg/kg을 1일 3회에 나누어 분할 투여하거나, 1일 1회 투여하였다. 임상적 효과와 독성 여부를 판정하고, gentamicin의 혈중 최고 농도와 최저 농도를 측정하였으며, 소변의 β₂-microglobulin과 N-acetyl-β-D-glucosaminidase를 측정하여 신독성 예측의 지표로 삼을 수 있는지 알아 보았다. 결과: 1)1회 투여군 19명, 분할 투여군 15명에서 모두 호전되었고, 미생물학적으로 원인균이 검출된 경우는 1회 투여군에서 19명 중 15명, 분할 투여군에서 15명 중 12명으로 모두 E.coli였으며, 치료 후에 모두 소실되었고, 신독성이나 이독성은 한 예도 없었다. 2)Gentamicin 혈중 최고 농도는 1회 투여군에서 평균 평균 14.79±5.71㎍/mL, 분할 투여군에서 5.33±1.99㎍/mL, 최저 농도는 1회 투여군에서 평균 0.35±0.45㎍/mL, 분할 투여군에서 0.69±0.58㎍/mL였다.. 3)분할 요법에서 gentamicin 혈중 최고 농도가 7.0㎍/mL 이상인 경우는 15예 중 2예, 5.0±㎍/mL 미만인 경우는 15예 중 7예였다. 4)소변의 β₂-microglobulin 농도는 두 군을 통털어 치료 전 2.71±2.20-㎍/mL, 치료 후 0.37±0.90㎍/mL이었고, N-acetyl-β-D-glucosaminidase 농도는 치료 전 8.67±7.39U/L, 치료 후 17.74±7.86 U/L였다. 결론:급성 신우신염환자에서 gentamicin 1일 1회 요법은 분할 요법과 비교하여 임상적, 미생물학적 효과 및 부작용에서 차이가 없는 것으로 나타났다. 위중한 그람 음성 간균 감염에서는 gentamicin의 분할 요법으로 적절한 혈중 최고 농도를 얻기 어려우며, aminoglycoside 사용시 소변의 N-acetyl-β-D-glucosaminidase를 측정하는 것이 신독성 예측의 지표가 될 수 있을 것으로 추측된다. Background: Once daily dose of aminoglycoside has been used recently in the gram-negative infection for the purpose of improving efficacy. The clinical efficacy and side effects of once daily versus divided doses of gentamicin were compared in acute pyelonephritis. Method: Gentamicin (3-5mg/kg/day) was administered into 3 divided doses intravenously in 15 patients of the divided dose group, and the same dose was administered at a time in 19 patients of the once daily dose group. The duration of treatment was 6-14 days. Results:The clinical outcome of all patients was favorable, and nephrotoxicity or ototoxicity was not detected in any patients. E. coli were isolated from 12 patients in the divided dose group, and 15 patients in the once daily dose group. They were all eradicated after treatment. The mean peak serum concentrations of gentamicin were 5.33±1.99㎎/mL in the divided dose group, and 14.79±5.71㎍/mL in the once daily dose group. The trough concentrations were not different significantly between two groups(0.69±0.58㎍/mL in the divided dose group vs. 0.35±0.45㎍/mL in the once daily dose group). The number of patients with peak concentration over 5.0㎍/mL were 8 out of 15 in the divided dose group. Conclusion: The once daily dose of gentamicin was as effective as the divided dose, and the nephrotoxicity or ototoxicity was not observed in both groups.

浸透壓을 利用한 浚渫埋立 地盤의 壓密特性 硏究

이규환,양태선,이송,성광용 대한토목학회 1994 대한토목학회 학술발표회 논문집 Vol.1994 No.1

원발성 간암에서 PIVKA-II 및 Lens Culinaris Agglutinin-A 반응성 Alpha-fetoprotein(AFP-L3)의 임상적 유용성

배시현,박두호,양진모,박영민,차상복,최종영,성광용,조세현,정규원,선희식,김부성,최상욱,변병훈,한남익 대한간학회 2000 Clinical and Molecular Hepatology(대한간학회지) Vol.6 No.2

Background/Aims: Des-γ-carboxy prothrombin(DCP), a protein induced by vitamin K absence or antagonist-II(PIVKA-II), and Lens culinaris agglutinin-A reactive AFP-L3 have been reported to be useful markers for the diagnosis of hepatocellular carcinoma (HCC). In the present study, both the PIVKA-II and AFP-L3 were analyzed and compared with a conventional AFP to determine its usefulness, specificity and sensitivity in the diagnosis of HCC. Methods: Sera were collected from 108 patients consisting of 17 patients with chronic hepatitis, 22 patients with liver cirrhosis and 69 patients with HCC. The AFP-L3 was determined by an lectin affinity electrophoresis coupled with an antibody-affinity blotting. Level of DCP was measured by an enzyme immunoassay with an anti-DCP monoclonal antibody. Results: The sensitivity and specificity of PIVKA-II and AFP L3 were 49.3% and 89.5%, and 32.5% and 85.7%, respectively. No significant correlation was found between the PIVKA-II or AFP L3 and serum AFP. No correlation was found etween the PIVKA-II or AFP L3 and the characteristics of HCC. Conclusion: The determination of plasma DCP and AFP L3 levels combined with AFP levels may be useful especially for the differential diagnosis between HCC and chronic liver diseases without HCC.(Korean J HepatoBackground/Aims: Des-γ-carboxy prothrombin(DCP), a protein induced by vitamin K absence or antagonist-II(PIVKA-II), and Lens culinaris agglutinin-A reactive AFP-L3 have been reported to be useful markers for the diagnosis of hepatocellular carcinoma (HCC). In the present study, both the PIVKA-II and AFP-L3 were analyzed and compared with a conventional AFP to determine its usefulness, specificity and sensitivity in the diagnosis of HCC. Methods: Sera were collected from 108 patients consisting of 17 patients with chronic hepatitis, 22 patients with liver cirrhosis and 69 patients with HCC. The AFP-L3 was determined by an lectin affinity electrophoresis coupled with an antibody-affinity blotting. Level of DCP was measured by an enzyme immunoassay with an anti-DCP monoclonal antibody. Results: The sensitivity and specificity of PIVKA-II and AFP-L3 were 49.3% and 89.5%, and 32.5% and 85.7%, respectively. No significant correlation was found between the PIVKA-II or AFP-L3 and serum AFP. No correlation was found etween the PIVKA-II or AFP L3 and the characteristics of HCC. Conclusion: The determination of plasma DCP and AFP-L3 levels combined with AFP levels may be useful especially for the differential diagnosis between HCC and chronic liver diseases without HCC.(Korean J Hepatol 2000;6:205-214)l 2000;6:205-214)

신기능이 정상인 신이식 환자에서 부갑상선 기능항진증의 빈도 및 혈청 Alkaline Phosphatase와의 관계

박주현,김용수,김영옥,장윤식,방병기,양철우,성용직,성광용 대한신장학회 1999 Kidney Research and Clinical Practice Vol.18 No.1

The hyperparathyroidism which causes renal osteodystrophy is a common complication in patients with end stage renal diseases. It is usually normalized after successful renal transplantation, but it remains in some renal transplant recipients. It is not well known whether hyperparathyroidism decreases bone mineral density in renal allograft recipients or not. To evaluate the incidence and predictive marker for hyperparathyroidism in renal allograft recipients and to describe the impact of hyperparathyroidism on the bone mineral density, we measured intact parathyroid hormone(iPTH) in 193 renal allograft recipients with stable renal and hepatic function. The mean age of patients was 42?12(13-76) years old and male female ratio was 1.9. The patients were on pre-transplant dialysis for 14.4?15.6(0-130) months and were followed up for 43.8?35.7(2-204) months after transplantation. Of the total 193 patients, 13 patients(6.7%) had high iPTH level. All patients showed normal serum calcium and phosphorous levels. i levels were positively correlated to pre- and post-transplant serum alkaline phosphatase levels(vs. pre-transplant r=0.32, P$lt;0.001, vs post-transplant r=0.63, P$lt;0.001). There was no difference in pre-and post-transplant serum calcium, phosphorus, post-transplant serum creatinine and hemoglobin levels between the patients. There were no statistical differences in age, sex, duration of pre-transplant dialysis, duration of post-transplant follow-up, number of transplantation, donor type, primary renal disease and episodes of acute rejection. Of the total 193 patients, bone mineral density was studied in 37 patients. Bone mineral densities did not correlated to iPTH levels. In conclusion, the incidence of hyperparathyroidism in renal allograft recipients with stable renal function was 6.7%. Pre-and post-transplant serum alkaline phosphatase levels might be used as a useful marker for hyperparathyroidism. Serum iPTH level was not correlated to bone mineral density.